Previous 10 | Next 10 |
Terns Pharmaceuticals ( NASDAQ: TERN ) has commenced a proposed underwritten public offering of $75M of shares of its common stock. In addition, the company expects to grant the underwriters a 30-day option to purchase additional shares. Actual size and terms of the offering a...
FOSTER CITY, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including o...
Summary Terns has a few molecules in early stages. These molecules are undifferentiated copies of existing, later stage molecules. The company hasn't gotten over its "transpacific" mindset of bringing American molecules into China. Terns Pharmaceuticals ( TERN ) is a small...
FOSTER CITY, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including o...
Terns Pharmaceuticals press release ( NASDAQ: TERN ): Q3 GAAP EPS of -$0.44 beats by $0.07 . As of September 30, 2022, cash, cash equivalents and marketable securities were $187.3 million as compared with $166.0 million as of December 31, 2021. Based on its current...
Terns plans to initiate U.S. clinical trial for TERN-701 (allosteric BCR-ABL inhibitor) in CML in second half of 2023 Positive data from Phase 1 trial of TERN-501 (THR-β agonist) in NASH presented at AASLD 2022, with top-line data from Phase 2a DUET trial expected in seco...
Data demonstrated treatment with TERN-501 resulted in time- and dose-dependent increases in sex hormone binding globulin (SHBG), a key marker linked to NASH histologic efficacy Phase 2a DUET trial evaluating TERN-501 alone and in combination with TERN-101, the first trial assess...
FOSTER CITY, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, inclu...
FOSTER CITY, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, inclu...
Summary Shares of biotech concern Terns Pharmaceuticals are up some 150% after consummating a secondary offering at $2.42 a share, announced on August 12, 2022. Despite the bump, shares of Terns Pharmaceuticals are still down significantly from their IPO pricing back in January 20...
News, Short Squeeze, Breakout and More Instantly...
Terns Pharmaceuticals Inc. Company Name:
TERN Stock Symbol:
NASDAQ Market:
Terns Pharmaceuticals Inc. Website:
2024-07-20 09:30:00 ET Eli Lilly and Novo Nordisk are, for now, the undisputed champions of the market for weight-loss medicines. Thanks to the outrageous popularity of Lilly's drug Zepbound and Novo's product Wegovy, the biggest contest of the moment will go to whoever can ramp up ...
2024-07-17 00:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
FOSTER CITY, Calif., June 21, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including o...